HCG, testosterone, and natural production: what TRT really does

What did @missvtrt__np actually say?

A nurse practitioner specializing in men's health argued that HCG (human chorionic gonadotropin) is not automatically necessary with TRT, but becomes "fantastic" when added to a testosterone protocol. She explained that HCG mimics luteinizing hormone (LH), which signals the testes to produce testosterone. Her core claim: if a man's LH is already high and his testes aren't responding, HCG won't help because, as she put it, "your balls are dead." She also warned that using HCG alone in secondary hypogonadism can "burn out those Leydig cells" and become suppressive. On the benefits side, she credited HCG with improving ejaculatory volume, reducing testicular atrophy, and preserving fertility. She called it "the Botox of my practice" but stopped short of calling it essential.

Does the science back this up?

Mostly, yes. The mechanistic claims here are well-supported, even if a few of the clinical assertions need more nuance than a TikTok allows.

The LH-mimicry mechanism is accurate. HCG binds to the LH/hCG receptor on Leydig cells, stimulating intratesticular testosterone (ITT) production. A frequently cited study by Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) confirmed that low-dose HCG co-administered with exogenous testosterone maintained ITT at levels sufficient to support spermatogenesis, even when serum LH was suppressed.

Her point about testicular atrophy and ejaculatory volume reduction during TRT is supported by Samplaski et al. (2013, Fertility and Sterility), which found that adding HCG to TRT preserved testicular volume and sperm parameters. The fertility preservation angle is not marketing fluff. It is clinically documented.

The claim that HCG alone can be suppressive in secondary hypogonadism is less commonly discussed and deserves more scrutiny than she gave it.

What did they get wrong (or right)?

She got the basics right. The LH mechanism, the distinction between primary and secondary hypogonadism, the role of HCG in fertility preservation, and the atrophy-reduction benefit are all consistent with published evidence and mainstream endocrinology guidance.

Where she oversimplified: the claim that HCG monotherapy "actually becomes suppressive" for men with secondary hypogonadism is not well-established in the literature. HCG can raise testosterone in secondary hypogonadism cases precisely because the Leydig cells are still responsive. Burnout from supraphysiologic stimulation is a theoretical concern, but the evidence base for HCG monotherapy causing meaningful Leydig cell desensitization at standard doses is not robust. Liu et al. (2002, Journal of Clinical Endocrinology and Metabolism) showed receptor downregulation is possible with high-dose, prolonged HCG use, but her blanket framing was too confident for what the data actually shows.

She also did not mention that compounded HCG is no longer available in the same regulatory landscape as pre-2020, and that some patients now receive kisspeptin or gonadorelin instead. That omission matters for clinical accuracy.

What should you actually know?

If you are on TRT and care about fertility or testicular volume, HCG has a real evidence base. It is not pseudoscience. The Coviello et al. data on intratesticular testosterone preservation is the clearest argument for its use alongside TRT in men who want to remain fertile or avoid atrophy.

However, HCG is not a universal add-on. Men with primary hypogonadism, where the testes themselves are non-functional, will not benefit from LH-mimicry of any kind. Her analogy about "yelling at a deaf person" is blunt, but mechanistically accurate.

A few practical caveats worth knowing:

• HCG does increase estradiol in many men, which may require monitoring or an aromatase inhibitor in some cases (Coviello et al., 2005).
• The FDA withdrew approval for compounded HCG in 2020; some clinics now use alternatives like gonadorelin. Formulations matter, and compounded products are not equivalent to FDA-approved branded versions.
• HCG is not approved by the FDA for use in TRT protocols specifically. It is used off-label for this purpose.
• If fertility is not a concern and you have no atrophy symptoms, the clinical case for adding HCG weakens considerably, which is actually consistent with what she said.

Bottom line

This video is more accurate than most TRT content on TikTok. The creator clearly understands the HPG axis and is not selling HCG as a miracle. Her oversimplification of HCG suppression in secondary hypogonadism is a real error, but it is a nuance, not a fundamental mistake. The fertility and atrophy claims are grounded in evidence. If you are managing your own TRT, discuss HCG with a licensed provider who can check your LH levels and determine whether your hypogonadism is primary or secondary before adding anything to your protocol.